The presence of multiple subclones within tumors mandates understanding of longitudinal
and spatial subclonal dynamics. Resolving the spatial and temporal heterogeneity of …

Lung cancer diagnostics have progressed greatly in the previous decade. Development of
molecular testing to identify an increasing number of potentially clinically actionable genetic …

As tumors grow, they acquire mutations, some of which create neoantigens that influence
the response of patients to immune checkpoint inhibitors. We explored the impact of …

Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through
human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the …

Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective …

The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …

The interplay between an evolving cancer and a dynamic immune microenvironment
remains unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell …

Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …

B cells are frequently found in the margins of solid tumours as organized follicles in ectopic
lymphoid organs called tertiary lymphoid structures (TLS),. Although TLS have been found to …

Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells
persisting after curative intent therapy. The study of large patient cohorts incorporating …